MMEDF Stock Valuation

MMEDF -  USA Stock  

USD 4.69  0.46  10.87%

What is the value of Mind Medicine today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Mind Medicine, is its stock price multiplied by the total number of shares outstanding, calculating Mind Medicine's enterprise value requires a different approach. It uses Mind Medicine's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Mind Medicine secures a last-minute Real Value of $3.44 per share. The latest price of the firm is $4.69. At this time, the firm appears to be overvalued. Our model forecasts the value of Mind Medicine from analyzing the firm fundamentals such as Current Valuation of 999.44 M, return on equity of (75.78) %, and Shares Owned by Insiders of 0.49 % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend purchasing undervalued stocks and exiting overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.

MMEDF Valuation 

Mind Medicine Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Mind Medicine's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
16th of October 2021
Please note that Mind Medicine's price fluctuation is very steady at this time. Calculation of the real value of Mind Medicine is based on 3 months time horizon. Increasing Mind Medicine's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Mind Medicine is useful when determining the fair value of the MMEDF stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Mind Medicine. Since Mind Medicine is currently traded on the exchange, buyers and sellers on that exchange determine the market value of MMEDF Stock. However, Mind Medicine's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Real Value
Estimating the potential upside or downside of Mind Medicine helps investors to forecast how MMEDF stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mind Medicine more accurately as focusing exclusively on Mind Medicine's fundamentals will not take into account other important factors:
LowEstimated ValueHigh

Mind Medicine Total Value Analysis

Mind Medicine is now forecasted to have takeover price of 999.44 M with market capitalization of 705.87 M, debt of 0, and cash on hands of 80.09 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Mind Medicine fundamentals before making investing decisions based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
999.44 M705.87 M080.09 M

Mind Medicine Asset Utilization

One of the ways to look at asset utilization of MMEDF is to check how much profit was generated for every dollar of assets it reports. Mind Medicine secures a negative usage of assets of -41.54 %, losing $0.42 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Mind Medicine shows how discouraging it operates for each dollar spent on its assets.

Mind Medicine Ownership Allocation (%)

Mind Medicine maintains a total of three hundred twenty-six million one hundred thirty thousand outstanding shares. Roughly 99.0 % of Mind Medicine outstanding shares are held by regular investors with 0.49 pct. owned by insiders and only 0.46 % by institutional investors. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 Ownership % 

Mind Medicine Profitability Analysis

Net Loss for the year was (35.34 M).

About Mind Medicine Valuation

The equity valuation mechanism determines the current worth of Mind Medicine on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Mind Medicine. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Mind Medicine based exclusively on its fundamental and basic technical indicators. By analyzing Mind Medicine's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Mind Medicine's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mind Medicine. We calculate exposure to Mind Medicine's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Mind Medicine's related companies.
Mind Medicine Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. Mind Medicine operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 22 people.

Mind Medicine Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Mind Medicine does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio33.69
Enterprise Value To Ebitda-31.34
Additionally, see Stocks Correlation. Note that the Mind Medicine information on this page should be used as a complementary analysis to other Mind Medicine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Tools for MMEDF Stock

When running Mind Medicine price analysis, check to measure Mind Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mind Medicine is operating at the current time. Most of Mind Medicine's value examination focuses on studying past and present price action to predict the probability of Mind Medicine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mind Medicine's price. Additionally, you may evaluate how the addition of Mind Medicine to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Bond Directory
Find actively traded corporate debentures issued by US companies
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal